MRVI Stock Overview
A life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MRVI from our risk checks.
Maravai LifeSciences Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.22 |
| 52 Week High | US$13.60 |
| 52 Week Low | US$4.52 |
| Beta | 0.056 |
| 1 Month Change | -36.22% |
| 3 Month Change | -9.98% |
| 1 Year Change | -47.61% |
| 3 Year Change | -83.79% |
| 5 Year Change | n/a |
| Change since IPO | -75.81% |
Recent News & Updates
RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One
Jun 12Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%
May 14
Recent updates
RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One
Jun 12Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%
May 14An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued
Apr 07Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Feb 28Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price
Dec 19Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates
Aug 14Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?
Feb 28Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 01Maravai Lifesciences temporarily reinstates Carl Hull as CEO
Oct 19Maravai LifeSciences appoints former Danaher executive as CEO
Oct 03Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M
Aug 04Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Jun 27Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price
Mar 29Maravai Faces Skeptical Investors As Pandemic Enters New Period
Jan 27Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk
Dec 02Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 26% Below Its Share Price
Oct 07Shareholder Returns
| MRVI | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -14.4% | -2.6% | 1.6% |
| 1Y | -47.6% | -1.0% | 21.5% |
Return vs Industry: MRVI underperformed the US Life Sciences industry which returned -0.9% over the past year.
Return vs Market: MRVI underperformed the US Market which returned 20.8% over the past year.
Price Volatility
| MRVI volatility | |
|---|---|
| MRVI Average Weekly Movement | 8.6% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MRVI's share price has been volatile over the past 3 months.
Volatility Over Time: MRVI's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 570 | Trey Martin | www.maravai.com |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing.
Maravai LifeSciences Holdings, Inc. Fundamentals Summary
| MRVI fundamental statistics | |
|---|---|
| Market cap | US$1.89b |
| Earnings (TTM) | -US$131.04m |
| Revenue (TTM) | US$274.10m |
3.5x
P/S Ratio-7.3x
P/E RatioIs MRVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRVI income statement (TTM) | |
|---|---|
| Revenue | US$274.10m |
| Cost of Revenue | US$153.40m |
| Gross Profit | US$120.70m |
| Other Expenses | US$251.74m |
| Earnings | -US$131.04m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 44.03% |
| Net Profit Margin | -47.81% |
| Debt/Equity Ratio | 67.3% |
How did MRVI perform over the long term?
See historical performance and comparison